Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Aug
10
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo